News

PFC is a pan-European contract research provider focused on drug and medical device development services and regulatory consulting. The combination of PFC and Clinipace Worldwide is expected to

The trial is being conducted under a Special Protocol Assessment (SPA) granted by the US Food and Drug Administration (FDA), which ensures that the agreed clinical trial design

In the trial, the company will investigate the safety and urate-lowering activity of arhalofenate 400mg and 600mg in around 60 patients with hyperuricemia. Arhalofenate’s eight Phase 1 and

The Vector, a real-life, prospective comparative study proved that the patients who received Vildagliptin and metformin did not experienced hypoglycaemic or severe hypoglycaemic events. However, the combination treatment

Under development by Cytheris, CYT107 is a critical immune-modulator for immune T-cell recovery and enhancement. Clinical trials including more than 180 patients in Europe, North America, South Africa

The increase in revenues is related to comparative higher-than-normal deliveries of Cetrotide to certain customers, as well as to the comparative strengthening of the euro against the US

Novozymes Biopharma claims the product offers optimal viscosity profiles for convenient application and increased patient comfort and compliance while superior heat stability permits autoclaving without loss of product

Graspa is a new enzyme formulation of L-asparaginase with a range of clinical uses compared to existing forms due to the enzymes entrapment and protection inside the homologous

XGEVA, a RANK Ligand inhibitor approved by the US Food and Drug Administration (FDA), is indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases